March, 2019

CBA Settlement of Disputed Claims for Software R&D Activities

March 18th, 2019

CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute re: the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]

Read More

Australia’s Attractiveness for Clinical Trials

March 6th, 2019

To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]

Read More

Email this job

[recaptcha]